TY - GEN
T1 - Photonic Crystal Enhanced Fluorescence with DNA-based Nano-gripper for Ultrasensitive Intact Viral Pathogen Biosensing
AU - Xiong, Yanyu
AU - Zhou, Lifeng
AU - Cooper, Laura
AU - Zheng, Mengxi
AU - Shepherd, Skye
AU - Dwivedy, Abhisek
AU - Song, Tingjie
AU - Hong, Wei
AU - Chen, Xin
AU - Liu, Shengyan
AU - Le, Linh T.P.
AU - Umrao, Saurabh
AU - Rong, Lijun
AU - Wang, Tong
AU - Wang, Xing
AU - Cunningham, Brian T.
N1 - The authors acknowledge the Imaging Facility of Advanced Science Research Center at GC of CUNY, the Electron Microscopy cores at the Materials Research Laboratory (MRL) at UIUC, and the Imaging Cores at the Carl R. Woese Institute for Genomic Biology (IGB) for the technical assistance. Funding: This work was supported in part by grants from NIH R21EB031310 (to X.W., and B.T.C.), NIH R44DE030852 (to X.W.), NSF-CBET 19-00277 (to B.T.C.), UIUC IGB Fellowship (to L.Z.), and C*STAR Fellowship from the Cancer Center at Illinois (to Y.X.).
PY - 2025
Y1 - 2025
N2 - We introduce a novel biosensing approach that utilizes photonic crystal-enhanced fluorescence technology integrated with a bioinspired DNA origami NanoGripper, selectively generating a fluorescent signal only upon detecting intact viral pathogens. Using intact SARS-CoV-2 as a representative example of a respiratory virus, this method demonstrates rapid, ultrasensitive, and highly selective biosensing. Photonic crystals (PC), serving as dielectric microcavities, provide substantial local field enhancement, far-field directional emission, large Purcell factors, and high quantum efficiency. These novel origami probes are coupled with a Photonic Crystal Enhanced Fluorescence Microscope, achieving a 10,000-fold signal enhancement compared to traditional single fluorophore reporters on glass substrates. Unlike surface-based ELISA assays, the capture reaction between the NanoGripper and the SARS-CoV-2 virus occurs in solution, reaching equilibrium within 10 minutes. After mixing, the mixture is pulled down to the PC surface for signal enhancement and direct counting. With virtually zero off-target signals, we achieve a limit of detection (LoD) of 100 viral genome copies per mL in human saliva, enabling ultra-high detection sensitivity.
AB - We introduce a novel biosensing approach that utilizes photonic crystal-enhanced fluorescence technology integrated with a bioinspired DNA origami NanoGripper, selectively generating a fluorescent signal only upon detecting intact viral pathogens. Using intact SARS-CoV-2 as a representative example of a respiratory virus, this method demonstrates rapid, ultrasensitive, and highly selective biosensing. Photonic crystals (PC), serving as dielectric microcavities, provide substantial local field enhancement, far-field directional emission, large Purcell factors, and high quantum efficiency. These novel origami probes are coupled with a Photonic Crystal Enhanced Fluorescence Microscope, achieving a 10,000-fold signal enhancement compared to traditional single fluorophore reporters on glass substrates. Unlike surface-based ELISA assays, the capture reaction between the NanoGripper and the SARS-CoV-2 virus occurs in solution, reaching equilibrium within 10 minutes. After mixing, the mixture is pulled down to the PC surface for signal enhancement and direct counting. With virtually zero off-target signals, we achieve a limit of detection (LoD) of 100 viral genome copies per mL in human saliva, enabling ultra-high detection sensitivity.
KW - Biosensing
KW - DNA-origami
KW - Enhanced Fluorescence
KW - Photonic Crystal
UR - http://www.scopus.com/inward/record.url?scp=105004416868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105004416868&partnerID=8YFLogxK
U2 - 10.1117/12.3043958
DO - 10.1117/12.3043958
M3 - Conference contribution
AN - SCOPUS:105004416868
T3 - Progress in Biomedical Optics and Imaging - Proceedings of SPIE
BT - Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XXII
A2 - Fixler, Dror
A2 - Wachsmann-Hogiu, Sebastian
PB - SPIE
T2 - Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XXII 2025
Y2 - 26 January 2025 through 28 January 2025
ER -